GlassScriptPhysician profile
Charles Maitland
NPI 1013914084
$13,740.27
in general payments reported to CMS, 2019-2025
38 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,797 · 2020: $1,358 · 2021: $2,660 · 2022: $2,950 · 2023: $2,486 · 2024: $1,391 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,942 · Education: $32.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,941.92 |
| Education | $32.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,665.65 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Emd Serono, INC. | $1,323.46 | 2019-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $1,186.45 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $838.91 | 2019-2025 | Ultomiris, Soliris |
| Genentech USA, INC. | $801.31 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Abbvie INC. | $688.95 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $645.35 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Kyowa Kirin, INC. | $619.09 | 2019-2024 | Nourianz |
| Horizon Therapeutics Plc | $566.88 | 2021-2023 | Uplizna |
| Genzyme Corporation | $476.21 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $458.39 | 2019-2025 | Nuplazid |
| Argenx US, INC. | $447.58 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Lilly USA, LLC | $436.97 | 2019-2025 | Kisunla, Amyvid |
| Ucb, INC. | $416.95 | 2023-2025 | Zilbrysq, Rystiggo |
| Mdd US Operations, LLC | $355.88 | 2019-2024 | Gocovri, Gocovri |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Maitland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.